Proposal of a program for applying the COVID-19 vaccine in minors

Propuesta de programa para la aplicación de vacuna anti-COVID-19 en menores de edad

José L. García-Vigil*

Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico

The federal plan for the application of the COVID-19 vaccine appears to me to be ethical, adherent to human rights, and based on the most important risk factors already identified in the Mexican population and adjusted for age distribution. At almost 11 months' duration of the pandemic in Mexico, evolution and real, not estimated, epidemiological results indicate the presence of SARS-CoV-2 genetic mutations, which increase ~70% the transmission capacity of the virus, which is increasingly infecting children and young people. For this reason, maybe it is time to adjust the vaccine application program and redirect it toward younger age groups, starting with those with known risks, all the more so given that, according to

the initial plan, they should be the last to be vaccinated. On the other hand, in the population younger than 18 years of age, the pharmaceutical industry has not recommended the application of any of the authorized vaccines, which is why it would be advisable approving them as emergency preventive treatment and carrying out clinical trials for this purpose in that age group.^{1,2}

References

1. Food and Drug Administration. FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine. United States: Food and Drug Administration; 2020.
2. Centers for Disease Control and Prevention. Vaccines and Immunization. Moderna Vaccine. United States: Centers for Disease Control and Prevention; 2021.

Correspondence:

*José L. García-Vigil

E-mail: pataloca5005@gmail.com

0016-3813/© 2021 Academia Nacional de Medicina de México, A.C.. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Date of reception: 01-02-2021

Date of acceptance: 10-02-2021

DOI: 10.24875/GMM.M21000589

Gac Med Mex. 2021;157:448

Contents available at PubMed

www.gacetamedicademexico.com